Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J. Lymp

Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (Nhl) With Lisocabtagene Maraleucel in the Outpatient Setting: Results From Two Phase 2 Trials

Hematological Oncology

English

Durable Responses After CD19-targeted CAR-T Cell Immunotherapy With Concurrent Ibrutinib for CLL After Prior Ibrutinib Failure

Hematological Oncology

English

Related publications

Safety of Lisocabtagene Maraleucel Given With Durvalumab in Patients With Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma: First Results From the Platform Study

Hematological Oncology

English

Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)

Hematological Oncology

English

Safety and Preliminary Efficacy in Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001

Hematological Oncology

English

Transcend CLL 004: Minimal Residual Disease After Lisocabtagene Maraleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Hematological Oncology

English

VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY

Hematological Oncology

English

Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma With the Anti-Pd-1, Tislelizumab: Results of a Phase 2, Single-Arm, Multicenter Study

English

Treatment of Relapsed and Refractory Hodgkin Lymphoma – Recommendations of the Czech Hodgkin Lymphoma Study Group

Klinicka Onkologie

Oncology

2016

English

An Ongoing Phase 1/1b Trial Investigating Novel Treatment Regimens With Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Hematological Oncology

English

A PHASE 2 CLINICAL TRIAL OF RITUXIMAB AND Β-Glucan PGG IN RELAPSED/REFRACTORY INDOLENT B-Cell NON-HODGKIN LYMPHOMA

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J. Lymp

Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (Nhl) With Lisocabtagene Maraleucel in the Outpatient Setting: Results From Two Phase 2 Trials

Durable Responses After CD19-targeted CAR-T Cell Immunotherapy With Concurrent Ibrutinib for CLL After Prior Ibrutinib Failure

Related publications

Safety of Lisocabtagene Maraleucel Given With Durvalumab in Patients With Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma: First Results From the Platform Study

Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)

Safety and Preliminary Efficacy in Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001

Transcend CLL 004: Minimal Residual Disease After Lisocabtagene Maraleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY

Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma With the Anti-Pd-1, Tislelizumab: Results of a Phase 2, Single-Arm, Multicenter Study

Treatment of Relapsed and Refractory Hodgkin Lymphoma – Recommendations of the Czech Hodgkin Lymphoma Study Group

An Ongoing Phase 1/1b Trial Investigating Novel Treatment Regimens With Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

A PHASE 2 CLINICAL TRIAL OF RITUXIMAB AND Β-Glucan PGG IN RELAPSED/REFRACTORY INDOLENT B-Cell NON-HODGKIN LYMPHOMA